Cargando…

Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia

Detalles Bibliográficos
Autores principales:	Verbeke, Delphine, Gielen, Olga, Jacobs, Kris, Boeckx, Nancy, De Keersmaecker, Kim, Maertens, Johan, Uyttebroeck, Anne, Segers, Heidi, Cools, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924552/ https://www.ncbi.nlm.nih.gov/pubmed/31976483 http://dx.doi.org/10.1097/HS9.0000000000000310

Ejemplares similares

PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia
por: Govaerts, Inge, et al.
Publicado: (2021)

Combination therapy of a PSEN1-selective γ-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemia
por: Vandersmissen, Charlien, et al.
Publicado: (2023)

Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing
por: Meyers, Sarah, et al.
Publicado: (2022)

Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping
por: Rack, Katrina, et al.
Publicado: (2022)

Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia
por: De Bie, Jolien, et al.
Publicado: (2018)

BCR-ABL1 positive B-ALL can undergo T-cell lineage shift to become CD19 negative T-ALL
por: De Bie, Jolien, et al.
Publicado: (2018)

TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia
por: Thielemans, Naomi, et al.
Publicado: (2022)

Age- and Intravenous Methotrexate-Associated Leukoencephalopathy and Its Neurological Impact in Pediatric Patients with Lymphoblastic Leukemia
por: Rijmenams, Ilona, et al.
Publicado: (2021)

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S, et al.
Publicado: (2018)

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S., et al.
Publicado: (2018)

Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia
por: Van Thillo, Quentin, et al.
Publicado: (2021)

SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia
por: García-Cañaveras, Juan C., et al.
Publicado: (2020)

Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia
por: Kalender Atak, Zeynep, et al.
Publicado: (2013)

t(1;7;22)(p13;q21;q13) is a novel 3-way variant of t(1;22)(p13;q13) neonatal acute megakaryoblastic leukemia: A case report
por: Messiaen, Julie, et al.
Publicado: (2023)

BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia
por: Tsuzuki, Shinobu, et al.
Publicado: (2022)

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2021)

Salidroside overcomes dexamethasone resistance in T-acute lymphoblastic leukemia cells
por: Niu, Ya-Na, et al.
Publicado: (2021)

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2019)

EML1–ABL1 Is Activated by Coiled-Coil-Mediated Oligomerization and Induces T-Cell Acute Lymphoblastic Leukemia or Myeloproliferative Disease in a Mouse Bone Marrow Transplant Model
por: Vanden Bempt, Marlies, et al.
Publicado: (2018)

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
por: Degryse, Sandrine, et al.
Publicado: (2015)

Mechanisms underlying transcription factor deregulation in acute lymphoblastic leukemia
por: Cools, Jan
Publicado: (2018)

Case report: Ruxolitinib plus dexamethasone as first-line therapy in haemophagocytic lymphohistiocytosis
por: Zhao, Lin, et al.
Publicado: (2023)

PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia
por: Silveira, André Bortolini, et al.
Publicado: (2015)

Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study
por: Stanevich, O. V., et al.
Publicado: (2021)

Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia
por: Heltemes-Harris, Lynn M., et al.
Publicado: (2011)

Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
por: Shi, Pei-Jie, et al.
Publicado: (2016)

The synthetic glucocorticoids prednisolone and dexamethasone regulate the same genes in acute lymphoblastic leukemia cells
por: Bindreither, Daniel, et al.
Publicado: (2014)

Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia
por: Ramsey, Laura B., et al.
Publicado: (2015)

Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia
por: Rizzuto, Giuliana, et al.
Publicado: (2022)

Transcription factor NKX2–1 drives serine and glycine synthesis addiction in cancer
por: Heylen, Elien, et al.
Publicado: (2023)

Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone
por: Warris, Lidewij T., et al.
Publicado: (2016)

The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM
por: Follin-Arbelet, Virginie, et al.
Publicado: (2015)

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
por: Mazzacurati, Lucia, et al.
Publicado: (2015)

Stat5 Synergizes with T Cell Receptor/Antigen Stimulation in the Development of Lymphoblastic Lymphoma
por: Kelly, John A., et al.
Publicado: (2003)

Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells
por: Kampen, Kim R., et al.
Publicado: (2019)

Identification of RNPC3 as a novel JAK2 fusion partner gene in B‐acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib
por: Chen, Xue, et al.
Publicado: (2019)

556. Ruxolitinib for the Management of Severe Pneumonia Caused by SARS-CoV-2. Exploring the Combination with dexamethasone
por: Molina, Aaron, et al.
Publicado: (2021)

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
por: Beagle, Brandon R., et al.
Publicado: (2014)

JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility
por: Lin, Minhui, et al.
Publicado: (2019)

Testicular relapse of acute lymphoblastic leukemia()
por: Carolan, Alexandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qp6qu6b5uon3v4kq2n6463qn04